1. Home
  2. ETNB vs DXPE Comparison

ETNB vs DXPE Comparison

Compare ETNB & DXPE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETNB
  • DXPE
  • Stock Information
  • Founded
  • ETNB 2018
  • DXPE 1908
  • Country
  • ETNB United States
  • DXPE United States
  • Employees
  • ETNB 93
  • DXPE N/A
  • Industry
  • ETNB Biotechnology: Pharmaceutical Preparations
  • DXPE Industrial Machinery/Components
  • Sector
  • ETNB Health Care
  • DXPE Industrials
  • Exchange
  • ETNB Nasdaq
  • DXPE Nasdaq
  • Market Cap
  • ETNB 1.2B
  • DXPE 795.0M
  • IPO Year
  • ETNB 2019
  • DXPE 1996
  • Fundamental
  • Price
  • ETNB $8.18
  • DXPE $80.37
  • Analyst Decision
  • ETNB Strong Buy
  • DXPE Buy
  • Analyst Count
  • ETNB 9
  • DXPE 1
  • Target Price
  • ETNB $29.63
  • DXPE $95.00
  • AVG Volume (30 Days)
  • ETNB 1.5M
  • DXPE 216.8K
  • Earning Date
  • ETNB 05-08-2025
  • DXPE 03-06-2025
  • Dividend Yield
  • ETNB N/A
  • DXPE N/A
  • EPS Growth
  • ETNB N/A
  • DXPE 8.63
  • EPS
  • ETNB N/A
  • DXPE 4.22
  • Revenue
  • ETNB N/A
  • DXPE $1,802,040,000.00
  • Revenue This Year
  • ETNB N/A
  • DXPE $4.88
  • Revenue Next Year
  • ETNB N/A
  • DXPE $4.07
  • P/E Ratio
  • ETNB N/A
  • DXPE $19.39
  • Revenue Growth
  • ETNB N/A
  • DXPE 7.35
  • 52 Week Low
  • ETNB $5.99
  • DXPE $43.25
  • 52 Week High
  • ETNB $13.71
  • DXPE $107.06
  • Technical
  • Relative Strength Index (RSI)
  • ETNB 42.49
  • DXPE 39.62
  • Support Level
  • ETNB $6.88
  • DXPE $70.76
  • Resistance Level
  • ETNB $9.40
  • DXPE $86.19
  • Average True Range (ATR)
  • ETNB 0.66
  • DXPE 4.91
  • MACD
  • ETNB -0.22
  • DXPE -0.72
  • Stochastic Oscillator
  • ETNB 30.27
  • DXPE 44.47

About ETNB 89bio Inc.

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

About DXPE DXP Enterprises Inc.

DXP Enterprises Inc is a distributor of products and services to industrial customers in the United States, Canada, Mexico, and Dubai. The company's reportable segments include Service Centers, Innovative Pumping Solutions and Supply Chain Services. It generates maximum revenue from the Service Centers segment. The company offers pumping solutions, supply chain services and maintenance, repair, operating and production services for rotating equipment, bearings and power transmissions, industrial supplies and safety products. DXP Enterprises serves the General Industrial, Oil & Gas, Food & Beverage, Water & Wastewater, Chemical, Transportation, Aerospace & Other.

Share on Social Networks: